Electronic Gateway Metrics and KPIs for Continuous Improvement Electronic Gateway Metrics and KPIs for Continuous Improvement In the evolving landscape of pharmaceutical regulatory affairs, efficient submission processes are pivotal. This article provides an in-depth exploration of the Electronic Gateway for submissions, specifically within the context of pharmacovigilance systems and the key performance indicators (KPIs) for continuous improvement. It is designed for Regulatory Affairs, CMC, and Labelling teams operating within the US, UK, and EU markets. Context The submission of regulatory documentation is central to the therapeutic development lifecycle. Regulatory agencies such as the FDA, EMA, and MHRA have adopted electronic…

How to Maintain Audit-Ready Electronic Gateway Documentation How to Maintain Audit-Ready Electronic Gateway Documentation Regulatory Affairs Context In today’s globally connected pharmaceutical landscape, the submission of regulatory documentation through electronic gateways has become a cornerstone for regulatory compliance. Regulatory Affairs (RA) professionals must navigate complex guidelines and adhere to stringent agency expectations while maintaining audit-ready documentation. This article aims to provide a comprehensive manual on how to ensure compliance in eCTD publishing and submissions through gateways such as the FDA Electronic Submissions Gateway (ESG), EMA’s Submission Portal, and the MHRA’s eSubmission Gateway. Legal and Regulatory Basis The regulatory framework governing…

Electronic Gateway: Regional Variations You Can’t Ignore Electronic Gateway: Regional Variations You Can’t Ignore The increasing complexity of regulatory submissions in the pharmaceutical industry has led to a growing reliance on electronic gateways. These platforms facilitate communication between companies and regulatory agencies such as the FDA, EMA, and MHRA. This article aims to provide an in-depth understanding of the electronic gateways and the regional variations that must be considered for successful submissions in the US, UK, and EU. Regulatory affairs professionals will learn how these variations affect submission workflows, documentation requirements, and compliance expectations with a special focus on regulatory…

Lessons Learned from Failed Electronic Gateway Submissions Lessons Learned from Failed Electronic Gateway Submissions Electronic Gateway Submissions (EGS) are critical components in the regulatory compliance landscape for pharmaceutical and biotech companies. These submissions ensure that essential documentation reaches regulatory authorities like the FDA, EMA, and MHRA efficiently and accurately. Recognizing the complexities and challenges faced in this arena is vital for Regulatory Affairs (RA) professionals to avoid pitfalls and streamline operations. This article explores the lessons learned from failed Electronic Gateway Submissions, emphasizing the importance of regulatory and compliance consulting, eCTD publishing, and submission workflows within the US, UK, and…

Electronic Gateway Governance Models for Global Operations Electronic Gateway Governance Models for Global Operations Context The landscape of regulatory submissions has evolved significantly with the advent of electronic submission platforms. Regulatory Affairs (RA) professionals are now tasked with navigating these digital channels, primarily focusing on maintaining compliance with both regulatory expectations and internal quality standards. This necessitates a robust understanding of the electronic Common Technical Document (eCTD) framework, particularly as it pertains to global electronic gateway submissions, which involve submissions through agencies like the FDA, EMA, and MHRA. Legal/Regulatory Basis The establishments of the FDA, EMA, and MHRA have developed…